Sands Capital

HAWK:AI GmbH is a fintech company based in Munich, Germany, founded in 2018. The company specializes in providing a money laundering detection and investigation platform that leverages machine-learning techniques to assist financial institutions in combating financial crime. HAWK:AI supports the end-to-end financial crime compliance process, encompassing transaction monitoring, investigation, filing, and maintaining audit trails. By focusing on effective information sharing, the platform enhances the capabilities of anti-money laundering and fraud surveillance teams within banks, payment companies, and fintech organizations, ultimately improving their efficiency and effectiveness in addressing financial corruption.

Flock Safety is a company that specializes in security solutions through the use of automated license plate recognition (ALPR) cameras. Its primary product, the ALPR camera system, is designed for use by neighborhoods, law enforcement agencies, and businesses to capture and analyze vehicle license plates. This technology aids in both preventing and solving crimes by providing actionable data to local authorities. Flock Safety's platform emphasizes community collaboration, integrating efforts from cities, businesses, schools, and law enforcement to enhance public safety. The company's full-service, maintenance-free technology is trusted by various communities as a means to deter crime and promote a safer environment for residents. Additionally, the system proactively alerts police when stolen vehicles enter monitored areas, enabling faster response and community involvement in crime prevention.

PgEdge provides distributed PostgreSQL designed to optimize the network edge, reduce data latency, and ensure ultra-high availability for mission-critical applications. The service combines multi-active, multi-master, and multi-region replication hosted in a managed cloud environment, enabling developers to build and deploy distributed database applications across the global network with low latency and resilient performance.

CompScience is a technology company that specializes in AI-driven solutions for the workers' compensation insurance sector, with a primary focus on enhancing workplace safety. The company develops a platform that utilizes machine learning algorithms to analyze historical data, allowing organizations to assess their safety protocols, identify potential hazards, and implement effective risk management strategies. By providing actionable insights, safety monitoring, and a user-friendly dashboard, CompScience helps businesses in logistics and manufacturing industries reduce injuries and lower workers' compensation costs. Additionally, the platform facilitates improved communication between safety teams and management, ensuring that safety initiatives align with organizational objectives and ultimately enhance employee well-being and operational performance.

Dreadnode specializes in developing offensive machine learning platforms tailored for cybersecurity. Its primary focus is research, evaluations, and cyber ranges to support machine learning in the cybersecurity domain.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Databricks offers a unified data analytics platform that simplifies data integration, enables real-time experimentation, and facilitates robust deployment of production applications for developers and data scientists. Serving diverse industries worldwide, Databricks' platform supports collaborative data science, machine learning workflows, and integrates with various cloud services.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders affecting the brain and other parts of the body. The company's lead product candidate, IkT-148009, is a c-Abl protein kinase inhibitor aimed at treating Parkinson's Disease, dysphagia, and neurogenic constipation. Additionally, Inhibikase is advancing IkT-001Pro, a prodrug of the anti-cancer agent Imatinib, which is designed to reduce gastrointestinal side effects. Other notable candidates include IkT-01427, which targets the virus responsible for progressive multifocal leukoencephalopathy, and the IkT-148x series, intended for Dementia with Lewy Body and Multiple System Atrophy. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase has also developed a small molecule platform that targets both bacterial and viral infectious diseases through a unified mechanism, aiming to create effective multi-pathogen anti-infectives while minimizing resistance development.

PgEdge provides distributed PostgreSQL designed to optimize the network edge, reduce data latency, and ensure ultra-high availability for mission-critical applications. The service combines multi-active, multi-master, and multi-region replication hosted in a managed cloud environment, enabling developers to build and deploy distributed database applications across the global network with low latency and resilient performance.

Anduril Industries is a defense technology company that designs, develops, and deploys hardware and software to address national security challenges for the United States and its allies. It offers the Lattice Platform, an AI-based system that fuses real-time data from computer vision, machine learning, and mesh networking into a single autonomous operating picture; Sentry Tower, which integrates data across the electromagnetic spectrum; Ghost sUAS, an unmanned autonomous, man-portable drone capable of performing missions with limited human intervention; and Anvil sUAS, a precision kinetic intercept that autonomously navigates to counter potential drone threats with visual verification by a human operator. Founded in 2017, Anduril is based in Irvine, California, with additional offices in Orange County, California; Washington, D.C.; and Seattle, Washington.

Credo AI is a company focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. Founded in 2020, it offers a sophisticated AI governance platform that automates oversight and risk management associated with AI technologies. This platform ensures continuous regulatory compliance with emerging global standards, including the EU AI Act and guidelines from NIST and ISO. By providing tools to measure, monitor, and manage risks linked to AI implementations, Credo AI helps businesses build customer trust, differentiate their offerings, and effectively manage potential challenges. The company has garnered recognition for its innovation, being listed among the CBInsights AI 100 and named a Technology Pioneer by the World Economic Forum, among other accolades.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Established in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on building enterprise voice assistants that engage in natural conversations with customers to address their needs. The platform utilizes advanced machine learning and natural language processing technologies, enabling it to understand and respond to customers effectively, regardless of the variations in their speech. Key features of PolyAI’s platform include multilingual support, dynamic flow design, and task-agnostic capabilities, allowing developers to create seamless and human-like interactions within various digital environments.

Ramp offers a comprehensive financial operations platform designed for businesses seeking to streamline their financial tasks. The platform includes corporate cards, expense management, bill payments, and accounting integrations, assisting organizations in managing their finances efficiently.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

HealthSnap develops a comprehensive virtual care management platform for healthcare organizations. Its solution enables remote patient monitoring, chronic disease management, and automated care coordination, aiming to improve patient outcomes while reducing utilization and diversifying revenue streams.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

LimaCharlie is a developer of a security infrastructure platform that focuses on managing cloud security through a Security Infrastructure as a Service (SIaaS) model. The company's platform offers a comprehensive suite of endpoint-driven information security tools, telemetry storage, and a complete incident response pipeline. It also features a hunting platform and a range of pre-made services, allowing businesses to customize their own detection and response rules. By delivering these security solutions on-demand and at scale, LimaCharlie significantly reduces costs and operational efforts for organizations, enabling them to effectively run Managed Security Service Providers (MSSP) or Security Operations Centers (SOC). Additionally, LimaCharlie provides APIs that empower users to build and monetize their own security products.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

SafeRide Health is a healthcare technology company specializing in non-emergency medical transportation. Its platform leverages AI and data analytics to enhance patient experience, improve population health, and optimize fleet management for healthcare providers.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Ramp offers a comprehensive financial operations platform designed for businesses seeking to streamline their financial tasks. The platform includes corporate cards, expense management, bill payments, and accounting integrations, assisting organizations in managing their finances efficiently.

OneTrust develops a comprehensive technology platform for privacy management. It automates privacy impact assessments, data inventory mapping, consent management, subject rights requests, incident reporting, and vendor risk management. The platform enables businesses to comply with global data privacy regulations across various sectors and jurisdictions.

Luminoah is a medical device company that develops a closed-loop, personalized enteral nutrition platform. This platform aims to enhance chronic disease care by offering a compact wearable pump, smart nutrition consumables, a patient-facing mobile app, and a provider intelligence platform. These tools enable real-time monitoring of patients' progress and improve adherence across both home and clinical environments.

Hungry is a Washington D.C.-based company that operates a food catering and delivery marketplace. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, Hungry connects independent chefs with businesses seeking high-quality catered meals. The platform offers a variety of prepared meals for different occasions, allowing businesses to order office lunches from a network of local chefs with curated menus. Hungry is committed to community improvement through initiatives like the ‘Fight Against Hunger’ program, which donates one meal to those in need for every two purchased, and the ‘WeRecycle’ program, which promotes environmental waste reduction by offering biodegradable plates and cutlery. The company has operations in several major U.S. cities, including Philadelphia, Atlanta, Boston, and New York City, with plans to expand its footprint to 23 cities by the end of 2021.

PgEdge provides distributed PostgreSQL designed to optimize the network edge, reduce data latency, and ensure ultra-high availability for mission-critical applications. The service combines multi-active, multi-master, and multi-region replication hosted in a managed cloud environment, enabling developers to build and deploy distributed database applications across the global network with low latency and resilient performance.

HAWK:AI GmbH is a fintech company based in Munich, Germany, founded in 2018. The company specializes in providing a money laundering detection and investigation platform that leverages machine-learning techniques to assist financial institutions in combating financial crime. HAWK:AI supports the end-to-end financial crime compliance process, encompassing transaction monitoring, investigation, filing, and maintaining audit trails. By focusing on effective information sharing, the platform enhances the capabilities of anti-money laundering and fraud surveillance teams within banks, payment companies, and fintech organizations, ultimately improving their efficiency and effectiveness in addressing financial corruption.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Tellius, Inc., established in 2015 and headquartered in Reston, Virginia, specializes in providing an AI-powered business analytics platform designed for enterprises seeking accelerated data-driven insights and decision-making. The company's core offering is a search-enabled visualization tool coupled with a proprietary recommendation engine that automates basic data interpretation using machine learning algorithms. This enables Tellius to uncover hidden correlations, trends, and anomalies within large datasets, presenting them as suggested visualizations and predictive models. Unlike traditional BI tools, Tellius' platform is built on Apache Spark, ensuring scalability and performance in big data environments.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Cleerly is a healthcare company developing digital care pathways to prevent heart attacks by establishing a new standard of care for coronary artery disease. The company combines clinical science with next-generation AI to deliver actionable insights across the heart care pathway, including a non-invasive platform that quantifies and characterizes plaque buildup in heart arteries. Its solutions aim to help healthcare providers identify at-risk patients early and support cost-effective prevention, ultimately improving cardiovascular outcomes and delivering value to the health system.

Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

Papercup specializes in automated video localization. Its software uses advanced neural networks and speech synthesis to translate voice tracks in videos, enabling content creators to reach global audiences efficiently and cost-effectively.

LimaCharlie is a developer of a security infrastructure platform that focuses on managing cloud security through a Security Infrastructure as a Service (SIaaS) model. The company's platform offers a comprehensive suite of endpoint-driven information security tools, telemetry storage, and a complete incident response pipeline. It also features a hunting platform and a range of pre-made services, allowing businesses to customize their own detection and response rules. By delivering these security solutions on-demand and at scale, LimaCharlie significantly reduces costs and operational efforts for organizations, enabling them to effectively run Managed Security Service Providers (MSSP) or Security Operations Centers (SOC). Additionally, LimaCharlie provides APIs that empower users to build and monetize their own security products.

Redbud Brands is a brand development studio that specializes in creating and scaling innovative consumer companies, particularly in the premium consumer packaged goods sector. The company collaborates with visionary founders and executives to develop disruptive brands that prioritize 'better-for-you' products. Redbud Brands offers a comprehensive platform that includes access to capital, a shared services network featuring experienced executives, and strategic relationships with retailers, distributors, and suppliers. This approach empowers entrepreneurs to launch and grow impactful brands that aim to make a positive contribution to society while achieving sustainable business success.

Credo AI is a company focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. Founded in 2020, it offers a sophisticated AI governance platform that automates oversight and risk management associated with AI technologies. This platform ensures continuous regulatory compliance with emerging global standards, including the EU AI Act and guidelines from NIST and ISO. By providing tools to measure, monitor, and manage risks linked to AI implementations, Credo AI helps businesses build customer trust, differentiate their offerings, and effectively manage potential challenges. The company has garnered recognition for its innovation, being listed among the CBInsights AI 100 and named a Technology Pioneer by the World Economic Forum, among other accolades.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Red Sift is a cybersecurity company that specializes in enhancing organizations' digital resilience through its comprehensive Digital Resilience Platform. This platform is designed to address vulnerabilities across an organization's entire digital footprint, offering advanced discovery and monitoring capabilities for email, domains, brand protection, and network perimeter security. By leveraging machine learning, Red Sift provides users with tools to analyze and synthesize data, enabling proactive threat detection and effective remediation strategies against phishing attacks while ensuring compliance with web security protocols. With a diverse client base that includes notable companies such as Domino’s, ZoomInfo, and various global law firms, Red Sift operates globally with offices in North America, Australia, Spain, and the UK, and collaborates with trusted partners like Entrust and Microsoft to enhance its offerings.

Speech Graphics Ltd is a company based in Edinburgh, United Kingdom, specializing in procedural facial animation technology for the entertainment industry. Founded in 2010, the company emerged from the University of Edinburgh's School of Informatics and has leveraged over 20 years of research and development in speech technology and facial dynamics. Speech Graphics offers SGX, a production software that transforms audio files and transcripts into high-quality facial animations without the need for motion capture. Their technology has been utilized in a variety of media, including AAA video games and music videos, and has applications in communication and training. The company has collaborated with prominent clients such as Warner Brothers and Def Jam Recordings and has received multiple awards for its innovative animation solutions, highlighting its impact on the industry.

Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.

Codoxo, formerly known as Fraudscope, is a company dedicated to enhancing the affordability and effectiveness of the healthcare system. It has developed a Forensic AI Platform that employs a patented algorithm to swiftly identify issues and suspicious activities within healthcare plans, surpassing traditional detection methods. This technology facilitates smart investigation and fraud detection, allowing investigators and analysts to gain valuable insights and conduct comprehensive investigations of questionable claims. By utilizing advanced AI-based capabilities, Codoxo aims to ensure that healthcare resources are allocated to genuine patient care, ultimately contributing to a more efficient healthcare environment.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Upgrade operates an online lending platform offering personal loans, the Upgrade Card, credit health monitoring, and educational tools. It serves both mainstream consumers and those underserved by traditional banking, aiming to provide affordable and responsible credit access.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Founded in 2017, Mekonos specializes in the development of gene and cell therapies. The company designs integrated system-on-a-chip technology to create predictive models for discovery and development, and operates a proprietary cell-engineering platform based on scalable silicon technology.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional office in Tel Aviv, Israel, SafeBreach offers a platform designed to enhance an organization's security posture by simulating real-world attack methods. The platform utilizes a comprehensive Hacker's Playbook, which includes a range of breach techniques derived from actual cyber incidents, to proactively identify vulnerabilities within an enterprise's network, cloud, and endpoints. By mimicking the tactics of cybercriminals, SafeBreach enables businesses to validate their security controls and improve the responsiveness of their security operations center (SOC) analysts. The platform can integrate with various security information and event management systems, ticketing solutions, and automation tools, providing continuous visibility into potential security threats and allowing organizations to address issues before they can be exploited by attackers.

SafeRide Health is a healthcare technology company specializing in non-emergency medical transportation. Its platform leverages AI and data analytics to enhance patient experience, improve population health, and optimize fleet management for healthcare providers.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Bridgit is a technology company that develops software for the construction industry, offering Bridgit Bench for resource planning and Bridgit Field for inspection, task and communication management. The platform helps contractors, developers, and builders manage workforce allocation, punch lists, deficiency tracking, and subcontractor coordination by aligning labor with availability and workload. Marketed as workforce intelligence for construction, Bridgit converts workforce data into actionable insights to support strategic and operational decision-making and improve project delivery and profitability. The company serves residential and commercial builders and partners with industry leaders. Bridgit was founded in 2014 and is headquartered in Kitchener, Canada.

Hungry is a Washington D.C.-based company that operates a food catering and delivery marketplace. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, Hungry connects independent chefs with businesses seeking high-quality catered meals. The platform offers a variety of prepared meals for different occasions, allowing businesses to order office lunches from a network of local chefs with curated menus. Hungry is committed to community improvement through initiatives like the ‘Fight Against Hunger’ program, which donates one meal to those in need for every two purchased, and the ‘WeRecycle’ program, which promotes environmental waste reduction by offering biodegradable plates and cutlery. The company has operations in several major U.S. cities, including Philadelphia, Atlanta, Boston, and New York City, with plans to expand its footprint to 23 cities by the end of 2021.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

JumpCloud operates a Directory-as-a-Service platform that securely manages and connects users to their systems, applications, files, and networks. Its cloud-based solution automates server management tasks such as user accounts, permissions, patches, security, and compliance. JumpCloud also provides identity management services for IT teams and businesses, enabling secure access to resources regardless of provider or location.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Established in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on building enterprise voice assistants that engage in natural conversations with customers to address their needs. The platform utilizes advanced machine learning and natural language processing technologies, enabling it to understand and respond to customers effectively, regardless of the variations in their speech. Key features of PolyAI’s platform include multilingual support, dynamic flow design, and task-agnostic capabilities, allowing developers to create seamless and human-like interactions within various digital environments.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

#Paid is a technology company that offers a creative marketing platform designed to facilitate collaboration between brands and social media creators. The platform enables brands to connect with a diverse array of artists, travelers, storytellers, and photographers globally, allowing for authentic product placements on social media. By transforming creator-generated content into paid advertisements, #Paid promotes engaging partnerships that enhance brand visibility and reach. With a focus on meaningful collaborations, the company streamlines the process for brands looking to leverage the influence of creators in their marketing campaigns.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Gusto is a SaaS company specializing in Human Capital Management. It offers a comprehensive suite of HR and payroll services, including payroll processing, benefits administration, time tracking, attendance management, and employee onboarding.

Exo is a medical device startup specializing in handheld ultrasound technology. It combines advanced materials, sensors, signal processing, and computation with semiconductor manufacturing economies to deliver affordable, high-quality imaging. This empowers healthcare professionals to make critical real-time decisions, enhancing patient outcomes.

Founded in 2015, BlackBuck is India's leading digital platform for truck operators and shippers. It streamlines logistics by connecting these parties online, enabling efficient load matching, reliable transportation, and seamless transactions. With a robust technology platform, BlackBuck facilitates payments, insurance, and financial services, benefiting millions of truckers and shippers alike.

Wugen is a biotechnology company developing off-the-shelf cellular therapies for cancer. It engineers memory natural killer (NK) cell and CAR-T therapies derived from healthy donors to deliver ready-to-use, consistent treatments that reduce production time and broaden patient access. The therapies target hematologic cancers and solid tumors, including acute myeloid leukemia and various T-cell malignancies.

Primer Technologies, Inc., established in 2014 and headquartered in San Francisco, specializes in developing software that leverages machine learning and natural language processing to analyze vast amounts of textual data across multiple languages. Its platform automates the parsing and collation of documents, uncovering insights and generating reports comparable to those produced by human analysts. This enables governments and corporations to better understand and monitor global information, facilitating informed decision-making.

Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.

Outreach is a sales engagement platform that helps organizations manage and optimize interactions across email, voice, and social channels throughout the customer lifecycle. The platform uses machine learning to guide sales representatives to take the right actions, automate repetitive tasks, and personalize communications while tracking sales activity and performance. It supports account-based, outbound, and inbound sales, as well as sequence and task management, email and activity tracking, and insights that analyze buyer sentiment to optimize content and sequences in real time. By integrating automated alerts, collaboration features, and performance analytics, Outreach aims to increase the volume of qualified meetings and improve the efficiency and effectiveness of customer-facing teams.

Founded in 2012 and headquartered in Boston with a London office, Klaviyo is a marketing automation platform specializing in email marketing for eCommerce businesses. It offers personalized newsletters, automated emails like abandoned cart reminders, and integrates natively with customer data sources.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Boom Entertainment is a technology company that specializes in developing a sports gaming application tailored for the sports betting industry. The company focuses on creating casual gaming experiences and offers both real-money and free-to-play online sports and casino games. Collaborating with professional sports leagues, media companies, and casino operators, Boom Entertainment aims to provide innovative gaming solutions that enhance user engagement. Its applications are designed to support business-to-business providers, facilitating access to real-money games for major casino operators.

Tellius, Inc., established in 2015 and headquartered in Reston, Virginia, specializes in providing an AI-powered business analytics platform designed for enterprises seeking accelerated data-driven insights and decision-making. The company's core offering is a search-enabled visualization tool coupled with a proprietary recommendation engine that automates basic data interpretation using machine learning algorithms. This enables Tellius to uncover hidden correlations, trends, and anomalies within large datasets, presenting them as suggested visualizations and predictive models. Unlike traditional BI tools, Tellius' platform is built on Apache Spark, ensuring scalability and performance in big data environments.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Luminoah is a medical device company that develops a closed-loop, personalized enteral nutrition platform. This platform aims to enhance chronic disease care by offering a compact wearable pump, smart nutrition consumables, a patient-facing mobile app, and a provider intelligence platform. These tools enable real-time monitoring of patients' progress and improve adherence across both home and clinical environments.

WireWheel, Inc. is a software company specializing in data privacy management solutions, designed to assist organizations in complying with various data protection regulations such as the EU GDPR and HIPAA. Established in 2016 and headquartered in Arlington, Virginia, WireWheel offers a cloud-based platform that integrates machine learning and data science to streamline privacy program management and subject rights request handling. The platform facilitates the automatic mapping of public cloud assets and aids in managing third-party relationships, enabling organizations to effectively navigate compliance obligations while maximizing the value of their data assets. WireWheel's innovative approach positions its clients to operationalize privacy effectively within their enterprises.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.

Coagulo Medical Technologies develops portable precision-medicine platforms for managing coagulation disorders. Its systems detect, identify, and quantify the effects of anticoagulants in whole blood, providing actionable results to healthcare providers.

Founded in 2015, StockX operates an online marketplace facilitating the buying and selling of limited edition sneakers. Its platform offers stock market-like visibility, enabling users to anonymously trade products, create personalized sneaker portfolios, and compare collections.

Uhnder Inc. is a technology company that specializes in developing innovative products for sensing, cognition, and communication within the Internet of Things (IoT) market. Founded in 2015 and headquartered in Austin, Texas, with additional engineering and operations in St. Louis, Uhnder is recognized for its digital automotive radar-on-chip. This technology serves as a more accurate and reliable alternative to traditional light detection and ranging (lidar) systems, enhancing the safety and responsiveness of autonomous vehicles. The chip is designed to prevent collisions, alert drivers to potential hazards, and facilitate quick localization for navigation. By offering this advanced solution, Uhnder aims to significantly improve the automation capabilities of manufacturers in the automotive sector.

Papercup specializes in automated video localization. Its software uses advanced neural networks and speech synthesis to translate voice tracks in videos, enabling content creators to reach global audiences efficiently and cost-effectively.

Founded in 2014, Brightflag is a global provider of AI-powered legal spend management software. It helps organizations control their legal expenses by processing billions of dollars annually, resulting in significant savings and time efficiencies.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Livermore, California, focused on discovering and developing therapeutics and diagnostics for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which selectively targets amyloid-beta oligomers, believed to be a significant contributor to the disease process. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in patient enrollment for clinical trials. The Phase 1 clinical trial for ACU193, initiated in the second quarter of 2021, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and target engagement among patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Results from this trial are anticipated by the end of 2022. Founded in 1996, Acumen Pharmaceuticals is committed to developing innovative approaches to address the challenges posed by Alzheimer's disease.

Scopely, Inc., established in 2011 and headquartered in Culver City, California, is a leading developer of mobile and tablet touchscreen-based games for casual and core gamers worldwide. The company creates, publishes, and live-operates immersive games, including popular franchises like "Star Trek™ Fleet Command," "MARVEL Strike Force," and "Stumble Guys." Scopely offers a range of services, such as game design, live operations, marketing, analytics, and advertising, empowering a consumer-directed gaming experience. With a diverse portfolio and a proprietary technology platform, Playgami™, Scopely has operations in multiple markets across Asia-Pacific, EMEA, and North America, employing a world-class team to create long-lasting game experiences.

Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.

BYJU'S is a prominent global ed-tech company founded in India in 2011, dedicated to providing adaptive and engaging learning solutions to over 150 million students worldwide. The company aims to make high-quality education accessible to learners of all ages through its flagship product, BYJU's: The Learning App, and a diverse portfolio that includes brands such as Disney-BYJU's Early Learn, BYJU's FutureSchool, and WhiteHat Jr. BYJU'S employs personalized learning methodologies that cater to individual learning styles and paces, supported by a network of over 12,000 teachers. The platform utilizes original content, watch-and-learn videos, animations, and interactive simulations to create a contextual and practical learning experience. Additionally, BYJU'S has formed innovative partnerships with major companies like Disney and Google to enhance engagement. Headquartered in India, BYJU'S operates in more than 21 countries and offers programs in over 8 languages, further solidifying its position as a leader in the education technology sector.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.